Loading
companiesCompany
NearWave
NearWave makes a handheld near-infrared scanner that shows within days whether a breast cancer is responding to chemotherapy before surgery, so patients are not left on a treatment that is failing.
Overview
NearWave's handheld device uses near-infrared diffuse optical imaging to measure haemoglobin, oxygenation, water and lipid content in breast tumours, tracking metabolic changes early in neoadjuvant chemotherapy to predict pathological response weeks before imaging or surgery would. It is a University of Notre Dame spin-out with clinical studies at US cancer centres. The device is investigational; predictive performance has been reported in early studies rather than a pivotal trial.
Headquarters
South Bend, IN, US
Funding
All startupsStartupYC W22
Investors
Stage
Startup · Y Combinator Winter 2022
Website
Similar pages
- CompanyClear Gene
Shares Y Combinator, HER2-positive breast cancer, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tag yc.
- CompanyBikanta
Shares Optical & fluorescence imaging, Y Combinator and the tag yc.
- CompanyiSono Health
Shares Y Combinator, HER2-positive breast cancer, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tag yc.
- CompanySignatur Biosciences
Shares Y Combinator, HR-positive / HER2-negative breast cancer and the tag yc.
- CompanyDigistain
Shares Y Combinator, HR-positive / HER2-negative breast cancer and the tag yc.
- CompanyAluna
Shares Y Combinator and the tag yc.
- CompanyMednet (theMednet)
Shares Y Combinator and the tag yc.
- CompanyAlixia
Shares Y Combinator and the tag yc.